Femasys Inc (FEMY) stock

FEMYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/3072% below fair value

$1.42+0.02 (+1.43%)

Close on Nov 13, 2026Market cap $11.89MP/E –Yield –

Femasys r&d expenses

Research and development expenses are spending on new products and technology.

Femasys's R&D Expenses for the twelve months ending Sep 30, 2026 was $7.01M, down 11.6% year over year. For fiscal 2025 it was $7.58M, down 7.8% from the year before. The highest annual figure on record is $8.22M in fiscal 2024.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$7.58M	-7.8%
FY2024	Dec 31, 2024	$8.22M	+14.0%
FY2023	Dec 31, 2023	$7.21M	+24.0%
FY2022	Dec 31, 2022	$5.81M	+42.3%
FY2021	Dec 31, 2021	$4.08M	-1.1%
FY2020	Dec 31, 2020	$4.13M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$1.94M	+40.6%
Q2 FY2026	Jun 30, 2026	$1.95M	+37.6%
Q1 FY2026	Mar 31, 2026	$1.31M	-55.9%
Q4 FY2025	Dec 31, 2025	$1.81M	-16.3%
Q3 FY2025	Sep 30, 2025	$1.38M	-40.0%
Q2 FY2025	Jun 30, 2025	$1.41M	-28.4%
Q1 FY2025	Mar 31, 2025	$2.97M	+67.6%
Q4 FY2024	Dec 31, 2024	$2.17M	+4.6%
Q3 FY2024	Sep 30, 2024	$2.30M	+11.1%
Q2 FY2024	Jun 30, 2024	$1.98M	+29.4%
Q1 FY2024	Mar 31, 2024	$1.77M	+15.2%
Q4 FY2023	Dec 31, 2023	$2.07M	+62.9%
Q3 FY2023	Sep 30, 2023	$2.07M	+25.8%
Q2 FY2023	Jun 30, 2023	$1.53M	+3.7%
Q1 FY2023	Mar 31, 2023	$1.54M	+8.2%
Q4 FY2022	Dec 31, 2022	$1.27M	+20.7%
Q3 FY2022	Sep 30, 2022	$1.65M	+44.5%
Q2 FY2022	Jun 30, 2022	$1.47M	+64.6%
Q1 FY2022	Mar 31, 2022	$1.42M	+42.8%
Q4 FY2021	Dec 31, 2021	$1.05M	+17.7%
Q3 FY2021	Sep 30, 2021	$1.14M	+14.6%
Q2 FY2021	Jun 30, 2021	$894.87K	+0.7%
Q1 FY2021	Mar 31, 2021	$995.02K	–
Q4 FY2020	Dec 31, 2020	$895.59K	–
Q3 FY2020	Sep 30, 2020	$995.62K	–
Q2 FY2020	Jun 30, 2020	$888.70K	–